Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstrating effectiveness in glioblastoma, melanoma, colorectal, pancreatic, and breast cancers. AGEN1721 works by remodeling the tumor microenvironment, depleting cancer-associated fibroblasts, and neutralizing TGFβ's immunosuppressive effects, transforming cold tumors into immune-responsive environments.
Agenus (NASDAQ: AGEN) presenterà nuovi dati su due promettenti candidati per l'immunoterapia durante il Congresso Annuale SITC 2024 a Houston. Le presentazioni riguarderanno botensilimab, un anticorpo anti-CTLA-4 potenziato con Fc che mostra efficacia nei tumori resistenti al trattamento, e AGEN1721, un anticorpo bifunzionale di prima classe che mira a FAP e TGFβ.
Botensilimab potenzia sia l'immunità innata che quella adattativa, dimostrando efficacia in glioblastoma, melanoma, tumori colorettali, pancreatici e al seno. AGEN1721 agisce rimodellando il microambiente tumorale, deplezionando i fibroblasti associati al cancro e neutralizzando gli effetti immunosoppressivi del TGFβ, trasformando i tumori
Agenus (NASDAQ: AGEN) presentará nuevos datos sobre dos prometedores candidatos para la inmunoterapia en la Reunión Anual SITC 2024 en Houston. Las presentaciones incluirán botensilimab, un anticuerpo anti-CTLA-4 mejorado con Fc que muestra eficacia en cánceres resistentes al tratamiento, y AGEN1721, un anticuerpo bifuncional de primera clase que apunta a FAP y TGFβ.
Botensilimab mejora tanto la inmunidad innata como la adaptativa, demostrando efectividad en glioblastoma, melanoma, cáncer colorrectal, cáncer de páncreas y cáncer de mama. AGEN1721 actúa remodelando el microambiente tumoral, depletando fibroblastos asociados al cáncer y neutralizando los efectos inmunosupresores de TGFβ, transformando tumores fríos en entornos inmuno-reactivos.
아게너스 (NASDAQ: AGEN)는 휴스턴에서 열리는 SITC 2024 연례 회의에서 두 가지 유망한 면역 요법 후보에 대한 새로운 데이터를 발표할 예정입니다. 발표 내용에는 치료에 저항력이 있는 암에서 효능을 보이는 Fc 강화 항-CTLA-4 항체인 보텐실리맙과 FAP 및 TGFβ를 표적으로 하는 최초의 이중 기능 항체인 AGEN1721이 포함됩니다.
보텐실리맙은 선천적 면역과 적응 면역을 모두 강화하여 교모세포종, 흑색종, 대장암, 췌장암 및 유방암에서 효과를 입증하고 있습니다. AGEN1721은 종양 미세 환경을 재구성하고 암 관련 섬유아세포를 고갈시켜 TGFβ의 면역 억제 효과를 무력화하여 차가운 종양을 면역 반응 가능한 환경으로 변화시킵니다.
Agenus (NASDAQ: AGEN) présentera de nouvelles données sur deux candidats prometteurs en immunothérapie lors de la Réunion Annuelle SITC 2024 à Houston. Les présentations porteront sur botensilimab, un anticorps anti-CTLA-4 amélioré par Fc qui montre de l’efficacité dans les cancers résistants aux traitements, et AGEN1721, un anticorps bifonctionnel de première classe ciblant FAP et TGFβ.
Botensilimab améliore à la fois l'immunité innée et adaptative, démontrant son efficacité dans le glioblastome, le mélanome, le cancer colorectal, le cancer du pancréas et le cancer du sein. AGEN1721 agit en remodelant le microenvironnement tumoral, en appauvrissant les fibroblastes associés au cancer et en neutralisant les effets immunosuppresseurs de TGFβ, transformant les tumeurs froides en environnements réactifs à l'immunité.
Agenus (NASDAQ: AGEN) wird beim SITC 2024 Jahresmeeting in Houston neue Daten zu zwei vielversprechenden Immuntherapie-Kandidaten präsentieren. Die Präsentationen werden botensilimab beinhalten, ein Fc-verbessertes anti-CTLA-4-Antikörper, das sich bei therapieresistenten Krebserkrankungen als wirksam erweist, und AGEN1721, ein erstklassiger bifunktioneller Antikörper, der auf FAP und TGFβ abzielt.
Botensilimab stärkt sowohl die angeborene als auch die adaptive Immunität und zeigt Wirksamkeit bei Glioblastom, Melanom, kolorektalen, Bauchspeicheldrüsen- und Brustkrebs. AGEN1721 wirkt, indem es das Tumormikroenvironment umgestaltet, krebserregende Fibroblasten abbaut und die immunsuppressiven Effekte von TGFβ neutralisiert, wodurch kalte Tumoren in immunantwortfähige Umgebungen verwandelt werden.
- None.
- None.
Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets
The first two presentations will spotlight botensilimab, an innovative, investigational, Fc-enhanced anti-CTLA-4 antibody that has shown remarkable efficacy in overcoming immune barriers across several treatment-resistant cancers, including glioblastoma, melanoma, colorectal, pancreatic, and breast cancers. Botensilimab’s unique mechanism of action enhances both innate and adaptive immunity to promote optimal T-cell priming, stimulate antigen-presenting cells, and deplete immune suppressing regulatory T cells in the tumor microenvironment, creating a multi-pronged attack on cold and refractory tumors.
“These findings represent a significant milestone in understanding how botensilimab can be optimally combined with both established and emerging therapies,” said Dr. Chand. “What’s particularly compelling is the profound efficacy we’re seeing in traditionally ‘cold’ tumors and treatment-resistant cancers—offering potential new options for patients with limited therapeutic choices.”
Featured botensilimab presentations:
Preclinical dose-pharmacokinetic-efficacy modeling of botensilimab using a mouse surrogate of the Fc-enhanced anti-CTLA-4 antibody |
527 |
Location: Exhibit Halls A B George R. Brown Convention Center Date: Friday, Nov. 8, 2024 - Odd Number Posters Poster Hall Hours: 9 a.m.–7 p.m. |
Fc-enhanced anti-CTLA-4 antibody, botensilimab, enhances the efficacy of multiple therapeutic modalities in immunotherapy-refractory tumor models |
720 |
Location: Exhibit Halls A B George R. Brown Convention Center Date: Saturday, Nov. 9, 2024 - Even Number Posters Poster Hall Hours: 9 a.m.–8:30 p.m. |
An additional presentation will cover AGEN1721, a first-in-class, Fc-enhanced bifunctional antibody targeting FAP and TGFβ. AGEN1721 is engineered to remodel the tumor microenvironment by depleting cancer-associated fibroblasts (CAFs) and neutralizing TGFβ’s immunosuppressive effects. By facilitating T-cell infiltration and activation, AGEN1721 effectively transforms cold tumors into "hot," immune-responsive environments.
“AGEN1721 represents a breakthrough in addressing the challenges of immune-excluded tumors by targeting key elements that suppress immune activity within the tumor microenvironment,” said Dr. Chand. “The data we’re presenting at SITC 2024 highlight how AGEN1721’s dual-action approach can dismantle barriers to immune infiltration, offering renewed hope for more durable and effective responses against resistant cancers.”
Featured AGEN1721 presentation:
AGEN1721, a first-in-class Fc-enhanced bifunctional antibody targeting FAP and TGFβ, remodels the tumor microenvironment to overcome cancer-associated fibroblast-mediated immune suppression |
1355 |
Location: Exhibit Halls A B George R. Brown Convention Center Date: Friday, Nov. 8, 2024 - Odd Number Posters Poster Hall Hours: 9 a.m.–7 p.m. |
About Botensilimab
Botensilimab is an investigational human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Approximately 1,100 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107623285/en/
Investors
917-362-1370
investor@agenusbio.com
Media
612-839-6748
communications@agenusbio.com
Source: Agenus Inc.
FAQ
What are the key findings for botensilimab presented at SITC 2024?
How does AGEN1721 work in treating resistant cancers?
When and where will Agenus (AGEN) present their immunotherapy data?
Which types of cancer does botensilimab target according to AGEN's SITC 2024 data?
